Current status of the diagnosis of Alzheimer’s Disease

Alzheimer’s disease needs an early diagnosis

In clinical practice to date, the diagnosis of Alzheimer´s Disease has only ever been possible at an advanced stage of the neurodegenerative process, when the patient has reached dementia and irreversible brain damage has occurred. An early diagnosis is essential.

Here at Araclon Biotech, we have developed our own kits (ABtest 40 and ABtest 42) which, together with the research studies we have carried out, have allowed us a direct determination of the beta-amyloid (Aβ) pool in blood. This is an important new concept in Alzheimer’s disease research, which enables us to quantify the quantity of all beta-amyloid 40 and 42 peptides in blood.

Currently at Araclon, we are carrying out studies involving more than 400 individuals, with the aim to obtain data which will allow us to validate our ABtest kits as indicative tools in the diagnosis of Alzheimer’s disease, and which will help clinical professionals to make an early diagnosis of the disease before the first symptoms appear.

Araclon research investigation